Philip Greenberg

Philip Greenberg is a pioneer in adoptive T cell immunotherapy and cancer vaccine development, having demonstrated that vaccination can prime and expand tumor antigen-specific T cells for adoptive transfer, creating a synergistic approach that combines vaccine-induced immunity with ex vivo T cell engineering. His work on WT1-targeted vaccines for leukemia has shown that cancer vaccines can generate measurable anti-tumor T cell responses when combined with appropriate adjuvants. He has characterized the requirements for adjuvant-driven T cell priming against weak tumor self-antigens versus strong neoantigens. His decades of work connecting vaccine immunology with cell therapy has advanced both fields.